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Background
IHR(2005)
In 2005, the World Health Assembly (WHA) adopted the 
revised International Health Regulations [IHR(2005)], 
which require 194 States Parties, including all the Member 
States of the World Health Organization (WHO), to 
develop core capacities to detect, assess, report, and 
respond to public health threats [1]. Th   e WHO is work-
ing with public and private sector partners around the 
world to help countries achieve IHR-mandated core 
capacities by 2012.
ASM LabCap Program
In 2005, the U.S. Centers for Disease Control and Preven-
tion (CDC), speciﬁ  cally the Division of Global HIV/AIDS 
(DGHA), formerly the Global AIDS Program (GAP), 
approached the American Society for Micro  biology (ASM) 
for assistance with capacity-building of global HIV and 
clinical microbiology laboratories in resource-constrained 
countries. Th   e CDC and ASM have since entered into two 
cooperative agreements (2005 and 2009), and ASM estab-
lished an International Laboratory Capacity Building 
Program, LabCap, housed under the ASM International 
Board. Th  e main mission of ASM LabCap is to utilize 
ASM’s vast resources and its member  ship expertise — 
40,000 microbiologists world  wide — to strengthen clinical 
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Public Healthand public health labora  tory systems in low and low-
middle income countries, primarily through the training 
and onsite mentoring of laboratory staﬀ  .  Th  e program 
began in 2006 as a result of the ﬁ  rst CDC/DGHA-ASM 
cooperative agreement.
ASM is well-equipped to play a major role in the global 
ﬁ  ght against infectious diseases. More than 5,000 ASM 
members are clinical microbiologists, many with years of 
experience developing laboratory quality assurance 
(QA)/quality control (QC) programs, managing labora-
tories, instituting good laboratory practices, providing 
training for performance of laboratory duties, and 
designing diagnostic tools and procedures. ASM LabCap 
rapidly engages these experts from around the world to 
develop and roll-out laboratory training and mentoring 
programs. Th   ese successful activities have to-date 
occurred in 17 countries: Botswana, China, Côte d’Ivoire, 
Guatemala, Guyana, Haiti, India, Kenya, Mozambique, 
Namibia, Nigeria, Rwanda, Tanzania, Th  ailand,  Vietnam, 
Zambia, and Zimbabwe.
As more countries move toward implementation of 
infectious disease surveillance programs, such as required 
by IHR(2005), the strengthening of clinical microbiology 
laboratories becomes increasingly impor  tant because 
they serve as the ﬁ  rst line responders to detect new and 
emerging microbial threats, re-emerging infectious diseases, 
the spread of antibiotic resistance, and the possibility of 
bioterrorism. In fact, IHR(2005) Core Capacity #8, 
“Laboratory”, requires that laboratory services be a part 
of every phase of alert and response, including detection, 
investigation and response, with laboratory analysis of 
samples performed either domes  tically or through colla-
bor  ating centers. States Parties thus need to establish 
mechanisms for providing reliable and timely laboratory 
identiﬁ   cation of infectious agents and other hazards 
likely to cause public health emer  gencies of national and 
international concern [2].
Although not speciﬁ  cally designed in the context of 
IHR(2005), ASM LabCap’s program activities align with 
this eﬀ   ort by building the capability of resource-con-
strained countries to develop quality-assured, laboratory-
based information which is critical to disease surveillance 
and the rapid detection of disease outbreaks, whether 
they stem from natural, deliberate or accidental causes. 
In the elaboration of its programs, ASM LabCap co-
ordinates eﬀ  orts with international and U.S. govern  ment 
(USG) agencies and non-proﬁ  t organizations such as the 
WHO, the U.S. Agency for International Develop  ment 
(USAID), divisions of the CDC, and other international 
organizations in order to maximize resources and ensure 
a uniﬁ  ed response.
ASM LabCap’s various programs directly contribute to 
global laboratory capacity building eﬀ  orts. Th  ese  activities 
include:
• U.S. President’s Emergency Plan for AIDS Relief 
(PEPFAR) initiatives
•  ASM LabCap-CDC training cooperation
• International Emerging Infections Program (IEIP) 
initiatives
•  ASM - Program for Appropriate Technology in Health 
(PATH) collaboration in India
•  Tuberculosis (TB) Indeﬁ  nite Quantity Contract (IQC) 
partnership with PATH, USAID
ASM LabCap programs and activities
PEPFAR initiatives
Under a renewed ﬁ  ve-year cooperative agreement with 
the CDC, ASM LabCap is collaborating with CDC/DGHA 
on capacity building of global HIV and clinical micro-
biology laboratories in resource-constrained countries, 
including Botswana, Côte d’Ivoire, Ethiopia, Guyana, 
Haiti, Kenya, Mozambique, Namibia, Nigeria, Rwanda, 
Tanzania, Vietnam, and Zambia, in support of CDC’s 
PEPFAR initiatives. Additional countries/regions that 
ASM LabCap will be supporting in 2011 via this agree-
ment include the Democratic Republic of Congo, Central 
Asian Republics, and Ukraine.
Under the direction of the U.S. Global AIDS Co-
ordinator’s Oﬃ   ce, CDC/DGHA is a partner in the uniﬁ  ed 
USG eﬀ   ort to implement PEPFAR. Th  e CDC’s long-
standing partnerships with ministries of health around 
the world support improvement of critical infrastructure 
and services to build sustainable national public health 
capacity and help resource-constrained countries prevent 
HIV infection and improve treatment, care, and support 
for people living with HIV/AIDS. ASM LabCap’s partner-
ship with CDC/DGHA has focused primarily on 
laboratory diagnostic strengthening for TB and other 
HIV/AIDS-related opportunistic infections (OIs). ASM 
LabCap staﬀ    and consultants travel to countries to 
provide onsite technical assistance and mentoring in an 
eﬀ  ort to help establish and fully transfer quality-assured 
laboratory diagnostic capacity to laboratorians. Ongoing 
activities include:
•  Assessing laboratory systems and laboratory capacity 
mapping
•  Mentoring and training of laboratory staﬀ  
•  Providing technical support for the customization and 
rollout of consensus training packages and programs
•  Assisting with the strengthening of laboratory quality 
systems, including development of QC procedures, QA 
programs, and standard operating procedures (SOPs)
•  Providing guidance for the standardization and selec-
tion of equipment and reagents
• Establishing, optimizing, and validating laboratory 
tech  niques and procedures
• Assisting with the establishment of national public 
health/reference laboratories
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networks
• Assisting with the coordination of infectious disease 
surveillance and outbreak response
• Developing national strategic plans for public health 
laboratory networks
•  Guiding the development or optimization of national 
laboratory policies
•  Assisting laboratories in their preparations for 
accreditation
• Developing a certiﬁ   cation program for laboratory 
personnel
Key elements of the IHR(2005) laboratory core capacities are 
laboratory capacity mapping, specimen collection, hand  ling, 
and transport, biosafety, laboratory-based investi  gation, 
QA, and reporting/communications [3]. ASM LabCap 
activities, as outlined above, are consistent with these 
except for laboratory-based investigation. Note Table 1, 
which outlines select ASM LabCap country activities.
ASM LabCap-CDC training cooperation
ASM LabCap has assisted CDC with developing and 
rolling out training events for laboratory personnel 
capacity building. Th   ese events include two international 
courses on Acid-fast bacilli (AFB) smear microscopy 
external quality assessment (EQA), one in English in 
Tanzania and one in French in Senegal; a national French-
language  Mycobacterium tuberculosis (Mtb) culture, 
identiﬁ     cation, and drug susceptibility testing (DST) in 
Côte d’Ivoire; seven national basic microbiology work-
shops in Botswana, Kenya, Mozambique, Tanzania, and 
Zambia; and a national workshop for laboratory support 
of enteric disease outbreak surveillance and response in 
Kenya. A brief description of these programs follows.
AFB Smear Microscopy EQA workshops – Tanzania and Senegal
ASM LabCap facilitated two ﬁ  ve-day workshops entitled 
“Strengthening AFB Smear Microscopy EQA Programs”, 
one in English in December 2009 in Dar es Salaam with 
participants from Angola, Bahamas, Barbados, Botswana, 
Ethiopia, Jamaica, Kenya, Lesotho, Malawi, Mozambique, 
Namibia, Rwanda, Swaziland, Tanzania, Vietnam, Zambia, 
and Zimbabwe, and a francophone version in August 
2010 in Dakar with participants from Senegal, Cameroon, 
Haiti, and Côte d’Ivoire. In line with Article 44 of the 
IHR(2005), which calls for States to share technical 
cooperation and assistance in order to strengthen and 
maintain public health capacities, these platforms 
allowed the participating countries to network and share 
experiences, challenges, best practices, and lessons 
learned from EQA implementation, as well as assess new 
opportunities to integrate AFB smear microscopy into 
other laboratory disciplines. ASM LabCap is providing 
follow-up support to many of the participating countries.
French-language Liquid Culture and DST course
From February 22 through March 5, 2010, ASM LabCap 
and CDC/PEPFAR-Côte d’Ivoire organized in Abidjan, 
Côte d’Ivoire, its ﬁ  rst course on Mtb culture, identi  ﬁ  -
cation and DST for French-speaking African labora-
torians. Scientists, managers, and technicians from the 
National TB Program and four major Ivorian TB labora-
tories attended the two-week course held at the National 
TB Reference Laboratory housed in the Pasteur Institute 
of Côte d’Ivoire (IPCI). Th   e course was the ﬁ  rst national 
training event in Côte d’Ivoire to help increase detection 
and reporting of multi-drug resistant (MDR)-TB using 
newer, more rapid technology. TB, in its MDR and 
extensively drug resistant (XDR) forms, is a disease with 
the potential of causing public health emergencies which 
fall within the scope of IHR(2005). Its early detection, 
control, and containment in endemic regions of Africa, 
such as Côte d’Ivoire, are steps towards improving 
international public health security.
Basic clinical microbiology course – Botswana, Kenya, 
Mozambique, Tanzania, and Zambia
ASM consultants have facilitated workshops on basic 
bench top procedures for clinical microbiology for a total 
of 145 participants thus far. Th   e goal of each workshop, 
as developed by an ASM LabCap Committee Member, 
was to enable clinical microbiology laboratory technolo-
gists to instruct clinicians on proper choice and collection 
of patient samples for microbiological studies, to properly 
handle the samples in the laboratory with respect to 
initial testing and culture processes, to adequately 
identify the major pathogens in each site (and to not 
report non-pathogens), and to perform necessary anti-
microbial susceptibility tests (AST) on those pathogens. 
Th  ese procedures are encompassed in a series of ﬂ  ow-
charts and are demonstrated with real cultures and 
organisms. Participants learned in the laboratory by 
performing the procedures themselves. A list of the 
reagents and simple supplies used in the laboratory were 
provided to the participants for training and QC 
purposes in their own facilities. ASM LabCap places 
consul  tants in-country to work with the various partici-
pating laboratories as a follow-up to the training.
Course topics covered during these workshops relevant 
to the IHR(2005) included procedures for AST, detection 
of Vibrio cholerae, and other pathogen-causing epidemic 
diarrheal diseases, meningococcal meningitis, and 
respiratory infections.
CDC-ASM Joint Workshop for Laboratory Support of Enteric 
Diseases Outbreak Surveillance and Response – Kenya
Since 2008, there have been ongoing diarrheal outbreaks 
in Kenya that have spread to several districts throughout 
the country, including Nairobi. Performing accurate and 
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of outbreaks has been challenging for Kenya’s District 
and Provincial hospitals, which have limited skills and 
resources. Consistent with IHR(2005)’s focus on 
strengthening laboratory-based surveillance systems for 
epidemic-prone diseases such as cholera, in October 
2009, 39 district-based laboratory technologists, surveil-
lance oﬃ   cers, and clinical oﬃ   cers convened in Nairobi 
for a workshop designed to build their capacity to provide 
support in enteric disease outbreak surveillance and 
response. Th  is  eﬀ   ort was a collaborative endeavor 
between CDC/GDD (Global Disease Detection) Kenya 
Table 1. ASM LabCap CDC/PEPFAR select program country activities
Botswana Cô  te  d’Ivoire Kenya Nigeria
Laboratory 
renovations 
Working with 3 TB labs, 
including NTRL to assist with 
laboratory renovation design 
plans to implement TB culture 
capacity.
Off  ering ongoing technical 
guidance on the renovations of 
2 national-level reference labs, 
which includes BSL-3 capacity, 
as well as provincial & district 
level labs
Off  ered TA to renovate 2 
national-level & 5 regional labs 
for implementation of new TB 
diagnostics.
Procurement of 
equipment & 
supplies
Assisted NRL to develop lists 
of equipment, reagent and 
supply needs for three national 
TB laboratories seeking to 
implement TB culture capacity.
Worked with Kenyan 
stakeholders to identify & 
provide a list of required 
equipment and supplies for 
the central & provincial level 
microbiology labs
National-
level training 
workshops
Worked with national team 
to customize the consensus 
AFB Smear Microscopy Training 
Package for Botswana & prepare 
a plan to roll out the training to 
lab workers nationally. 
Together with CDC & national TB 
TWG, customized & rolled-out 
ASM-translated ACILT French TB 
culture & DST course at NTRL.
With the Central Microbiology 
Reference Laboratory (CMRL), 
conducted basic microbiology 
workshops for Provincial and 
District Level-5 laboratory 
technologists
Assisted with facilitating 
national-level molecular biology 
training events to reinforce new 
diagnostic methods.
National EQA 
schemes
Conducted a pre-
implementation assessment 
of Botswana’s existing TB and 
Bacteriology EQA program 
then worked with the national 
EQA Unit and National Health 
Laboratory to develop a 
comprehensive expansion 
plan & the supporting 
documentation (forms, 
procedures, and electronic 
databases).
Off  ered TA to NTCP to help 
implement blinded rechecking 
of sputum smears & strengthen 
supervisory visit methodology 
for the national TB microscopy 
EQA program.
Off  ered TA to assist 
establishment of national EQA 
schemes to monitor quality, 
initially as related to a national 
drug resistance survey.
Establishment/ 
expansion of 
National Reference 
Laboratory
 Assisted with the improvement 
of antimicrobial resistance 
surveillance.
Working with NRL to redefi  ne 
core functions for microbiology, 
STIs & TB.
Working with NPHLS & CDC-
Kenya to defi  ne & establish the 
core functions of the CMRL.
SOPs Technical guidance off  ered 
review & revision of national 
SOPs, including standardizing 
procedures & forms for the 
national QA program & AST.
Worked with NPHLS & CMRL 
staff   to identify essential tests 
for the CMRL & develop the 
corresponding SOPs; developing 
national microbiology SOPs.
Reviewed & recommended 
updates to 31 technical SOPs 
for TB to be used as nationally-
approved standardized SOPs.
National Strategic 
Planning & Policy 
Development
Working with NHL’s 
Microbiology Laboratory to 
expand services and strengthen 
microbiology services nationally. 
Assisted with formulating a 
strategic plan to upgrade the 
NHL’s capacity & transfer routine 
testing to a new hospital lab.
Participated in MOH-driven 
National Strategic Planning 
Workshop for TB, HIV and Malaria 
labs & off  ered recommendations 
for integrating lab services, as 
well as assisting with guiding 
elaboration of key policy 
documents.
WHO-AFRO & 
international 
accreditation
Assisting, via onsite mentoring, 
2 national-level labs with 
achieving WHO-AFRO 
accreditation status, using ASM-
translated disease specifi  c & lab 
management training modules. 
Mentoring the CMRL and 
provincial microbiology 
labs to achieve WHO/AFRO 
accreditation goals.
Assisting, via onsite mentoring 
& technical guidance, 3 
national-level labs with 
incorporating QMS principles 
toward achieving WHO-AFRO 
accreditation status. 
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(FELTP), the Kenyan Ministry of Public Health and 
Sanitation (MoPHS), the CDC National Center for 
Emerging, Zoonotic & Infectious Diseases (NCEZID) in 
Atlanta, CDC/DGHA, and ASM LabCap. Th  e course 
illustrated the critical link between epidemiology, 
outbreak investigation, and both rapid and traditional 
detection by the laboratory.
Th   e trainees were presented with the basic principles of 
epidemiology and outbreak detection; determination of 
proper samples to collect in an outbreak; collection, 
packaging, and transport of biological samples from an 
outbreak; and rapid testing for detection of Vibrio 
cholerae, Shigella dysenteriae Type 1, Salmonella enterica 
serovar  typhi, and Shiga toxin-producing E. coli from 
biological samples. Furthermore, ASM LabCap facili-
tators discussed essential microbiological procedures and 
techniques for processing samples and traditional 
methods for culture, identiﬁ   cation and susceptibility 
testing of the four enteric pathogens. Overviews of Gram 
staining, laboratory diagnosis of common HIV-related 
OIs and other outbreak pathogens, QC, and media 
preparation were also included.
International Emerging Infections Program (IEIP) initiatives
IEIP is an international eﬀ  ort by the CDC as part of its 
Global Disease Detection Program to built capacity 
around the world to detect emerging infectious disease. 
ASM LabCap is providing technical expertise and 
consultation for building laboratory capacity and improv-
ing clinical microbiology for the diagnosis of respiratory 
diseases in select IEIP sites. Each site is set to implement 
active, population-based surveillance for pneumonia 
with varying levels of microbiological capacity. Below are 
descriptions of the IEIP sites that ASM LabCap has 
supported to-date, and the speciﬁ  c support provided by 
ASM.
China
Th  e U.S. CDC and China’s CDC collaborate to conduct 
active surveillance for patients hospitalized with 
community-acquired pneumonia in China. A three-
month pilot project evaluating procedures for patient 
enrollment and specimen collection, transport, testing, 
and reporting, was conducted from mid-November 2008 
to February 2009 in three sites (Panjin, Liaoning 
Province; Jingzhou, Hubei Province; Zhuhai, Guangdong 
Province). Patients enrolled in this study had specimens 
collected for microscopic examination, bacterial culture, 
viral culture, urine antigen testing, and polymerase chain 
reaction (PCR)-based identiﬁ   cation. During the pilot, 
ASM LabCap evaluated the capacity at each site to 
perform non-PCR based testing, to provide guidance 
regarding necessary supplies and equipment at each site, 
and to write SOPs. ASM LabCap also provided additional 
technical guidance for the ﬁ   nalization of the study 
protocol.
Guatemala
ASM LabCap worked with the CDC-Guatemala oﬃ   ce for 
Central America and Panama and the Guatemalan 
Ministry of Health to provide technical expertise and 
consultation for improving the diagnosis of respiratory 
diseases in Guatemala. ASM LabCap visited labs in 
Guatemala City and Cuilapa and reviewed blood culture 
processing and provided recommendations for improving 
species identiﬁ  cation, particularly Streptococcus pneumoniae, 
using the available BacT/Alert automated blood culture 
system. ASM LabCap additionally oﬀ  ered guidance for 
optimizing susceptibility testing via disk diﬀ  usion.
Thailand
Th  e  Th   ai provinces of Nakhon Phanom and Sa Kaeo are 
part of an active-population based surveillance system 
for community-acquired pneumonia under a Th  ai  Minis-
try of Public Health (MOPH) - U.S. CDC collaboration. 
Each has a major hospital with additional small hospitals 
and clinics. ASM LabCap evaluated procedures for 
specimen collection, transport, processing, culture, and 
identiﬁ  cation primarily for the detection of Streptococcus 
pneumoniae and provided recommendations to improve 
and reﬁ  ne their procedures.
ASM-PATH collaboration in India
Th  e Government of India has allocated substantial 
funding for developing integrated disease surveillance, 
with laboratory capacity building as an essential 
component and TB as a targeted disease for improved 
surveillance. Since November 2008, ASM LabCap has 
been working with PATH, on a USAID-funded initiative, 
to strengthen the capacity of the Intermediate Reference 
Laboratory (IRL) network to perform Mtb culture and 
DST (expected to expand to one IRL/state or territory or 
over thirty laboratories). Th  e ultimate goal of this 
initiative is to ensure that selected IRLs obtain national 
accreditation, i.e., be deemed fully proﬁ   cient in Mtb 
culture and DST by an overseeing National Reference 
Laboratory (NRL). States (or territories) with accredited 
IRLs will then be able to conduct drug resistance surveys 
(DRS) and implement the DOTS-Plus strategy to treat 
MDR-TB.
Activities performed by ASM LabCap thus far include:
• An in-depth onsite evaluation of IRLs in 8 states – 
Orissa, Haryana, West Bengal, Jarkhand, Uttarakhand, 
Uttar Pradesh, Chhattisgarh and Tamil Nadu – using a 
new comprehensive, customized IRL assessment tool. 
Th   e ASM LabCap consultants’ reports constituted the 
basis for development of accreditation work plans.
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and troubleshooting for equipment at IRLs, and a 
Biosafety Manual.
• Oﬀ  ering recommendations for the organization of an 
NRL/IRL Workshop held in November 2009. It was 
the ﬁ  rst time that microbiologists from IRLs had the 
opportunity to come together and share their experi-
ences in the presence of their NRL supervisors and 
peers. Th   e workshop was facilitated by, among others, 
the ASM LabCap consultant, who guided the technical 
discussions; it was so successful that it has now been 
decided to hold such a workshop twice yearly.
TB Indefi  nite Quantity Contract (IQC) partnership with 
PATH, USAID
ASM LabCap is also engaged in eﬀ  orts to control wide 
scale infectious disease, such as TB. In 2009, through 
USAID’s TB IQC, ASM partnered again with PATH in a 
consortium that also includes the Foundation for Inno-
vative New Diagnostics (FIND), Partners in Health, 
University of California-San Francisco (UCSF), Manage-
ment Sciences for Health (MSH), Brigham and Women’s 
Hospital, and Initiatives, Inc. Th   e purpose of the program 
is to provide extensive support to USAID operating units 
in the implementation of their TB control and prevention 
programs through the introduction and expansion of the 
components of the WHO-recommended STOP TB 
Strategy. Th   e TB IQC places special emphasis on MDR-
TB prevention and control and strengthening TB 
laboratory capacity.
Conclusion
Th   e IHR(2005) core capacity laboratory requirements are 
bringing new challenges for national laboratory systems; 
these requirements include improved diagnostic capacity, 
better connectivity intersectorally and internationally, 
and better quality of laboratory data and reporting. 
Public health diagnostic laboratories in many resource-
constrained countries lack laboratory involvement in 
disease surveillance, advocacy or resources, supporting 
infrastructures, biosafety awareness and practices, and 
pathogen security practices [3]. Th  ese countries require 
ﬁ  nancial and technical assistance to build their diagnostic 
laboratory capacity.
ASM LabCap, through partnerships with the WHO, 
CDC, and USAID, among others, has been assisting 
various WHO States Parties with acquiring needed 
laboratory diagnostic capacity, both as related to human 
resource and infrastructural developments. Th  ese 
activities are providing resource-constrained countries 
with the necessary tools to improve their public health 
laboratory infrastructure, which will enable them to 
move towards compliance with IHR(2005) requirements. 
Th  e scope of ASM LabCap’s work enables indigenous 
laboratorians to more rapidly and eﬀ  ectively identify and 
respond to a broad spectrum of diseases of public health 
relevance. Th  e activities are designed around creating 
sustainability and primarily focused on human resource 
development, speciﬁ   cally involving local entities in 
designing and customizing laboratory training tools that 
address their particular needs while still meeting 
international standards.
Th  rough the achievements of programs such as ASM 
LabCap, there is an increased visibility of the critical role 
laboratories play in health systems, helping advocacy 
eﬀ  orts and garnering additional resources for laboratory 
capacity building eﬀ  orts, as well as promoting the full 
integration and participation of laboratorians in the 
planning and implementation of national and inter-
national disease surveillance systems. Furthermore, ASM 
LabCap’s targeted training and mentoring programs are 
transferring quality-assured laboratory skills to labora-
torians with outcomes that indicate that the quality of the 
laboratory data are greatly improving, including data 
recording and reporting mechanisms. ASM LabCap is 
implementing in each of the supported laboratories a 
quality management system (QMS) approach that 
emphasizes the use of SOPs, guidance documents, QA/
QC procedures, biosafety practices and participation in 
successful EQA schemes; moving the laboratories toward 
international accreditation is a key activity of ASM 
LabCap.
In 2006, the WHA made a resolution relative to the 
immediate and voluntary compliance with IHR(2005); it 
included a request to “expand and accelerate training 
eﬀ   orts in the areas of…laboratory capacity, including 
regional networking of laboratories, biosafety, and quality 
control…”, and in 2008, the WHA resolved to pay close 
attention to the sub-Saharan African laboratory network 
[4]. ASM LabCap is actualizing an accelerated response 
to deﬁ   ciencies in laboratory capacity in many sub-
Saharan African countries by helping the countries deﬁ  ne 
and implement laboratory policies and guidance 
documents, map their public health laboratory capacity, 
develop human resources capable of implementing 
IHR(2005) laboratory core capacity requirements, oﬀ  er 
laboratory services to test for priority health threats, 
institute laboratory biosafety and biosecurity practices, 
and network on a regional and international level, in 
support of Article 44 of IHR(2005), and expressed in the 
2006 and 2008 WHA resolutions.
Meeting IHR(2005) requirements by 2012 will require a 
great deal of partner collaborations and coordination. 
Th  e USG is increasing its engagement in IHR(2005) 
capacity-building. As ASM LabCap is currently primarily 
supported by USG agencies as a technical arm for 
assisting low and low-middle income countries with 
improving their laboratory disease detection capacity, it 
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conceptualized in the context of IHR(2005). In addition, 
ASM LabCap will continue its active collaboration with 
the WHO and other international organizations in order 
to further coordinate eﬀ   orts for building integrated 
disease surveillance and response capabilities worldwide.
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